◈ Nootpedia
Compact view
Research pass: quick Peptide · Injectable SKIP-FOR-NOW LOW

Vesugen

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW LOW

Khavinson family broad skepticism stands for Vesugen specifically — and the case for Vesugen is even thinner than for pinealon. KED has only one mildly-cited co-result in the 5xFAD-M dendritic spine paper (and even there EDR/Pinealon was the stronger arm), the "vascular bioregulator" claim is essentially monograph-only, and Western replication is zero. For a 20yo MMA athlete with brain-priority (#1) and intact vasculature, there is no compelling mechanism-aligned use case. Would only revisit if (a) independent (non-Khavinson) replication of any vascular endpoint published, (b) Dylan develops vascular pathology requiring a peptide-level intervention, or (c) bloodwork (~June 2026) flags endothelial / vascular markers that no first-line option addresses better.

Research pass: quick
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Vasculature is intact, brain priority is #1, evidence base is the thinnest in the Khavinson family for this peptide, and Cerebrolysin / Semax / Adamax already cover the brain-protective peptide role with substantially better evidence. Vesugen earns no slot in this stack.

  • 30-50, executive maintenance
    SKIP-FOR-NOW

    Same logic. If vascular aging becomes a concern, citrulline / beetroot / regular cardio / lipid management / blood-pressure control all dominate Vesugen on evidence.

  • 50+, mild vascular aging concerns
    OPTIONAL-ADD

    at most. If running an existing Khavinson longevity stack (epithalon + pinealon), adding Vesugen during one cycle to test subjective response is defensible — but this is a "complete the family" addition, not foundational. Cardiovascular guideline-directed therapy (statin if indicated, BP control, exercise) dominates.

  • Active vascular pathology (post-stroke, peripheral arterial disease)
    OPTIONAL-ADD

    as adjunct, not substitute. Russian clinical tradition uses KED-class peptides as adjuncts to standard therapy. Western-evidence-graded therapies remain first-line. If pursuing peptide adjunct in this context, do so with cardiology input, not as DIY.

  • Anxiety-prone / sleep-disordered / strength-anabolic / recovery-focused
    NEUTRAL

    Not in Vesugen's claimed lane.

  • High athletic load, tested status
    N

    on WADA prohibited list as of 2026, but the broader S0 ("non-approved substances") clause could theoretically be invoked. Untested (Dylan): irrelevant.

▸ Subjective experience (deep)

Onset: Days to weeks, if any. Same profile as other Khavinson short peptides — not an acute-effect compound.

Peak / character: Most users describe nothing perceptible across a 20-30 day cycle. A minority report subtle "vascular" subjective effects — warmer hands/feet, slightly improved exercise recovery, perceived skin tone. None of this is biomarker-confirmed and all of it is consistent with placebo or stack confounds.

Characteristic absences:

  • No stimulant effect, no jitter, no appetite suppression
  • No noticeable acute "feel" within an hour of dose
  • No crash on cessation

For Dylan's archetype (already-optimized 20yo, intact vasculature, no vascular pathology, brain priority #1): expect nothing subjectively detectable. The case for Vesugen, if made, is on prophylactic vascular-aging grounds, not subjective performance — and at 20 the vascular-aging case is essentially zero.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown / not characterized.
  • Recommended cycle: 20-30 days on, every 4-6 months. Canonical Khavinson protocol.
  • No physical dependence, no withdrawal.
▸ Stacking deep dive

Synergistic with (theoretical, not demonstrated)

  • epithalon — co-administered partner in some "vascular + pineal" longevity protocols. Theoretical only; no head-to-head data showing additive benefit.
  • pinealon — same originating group, sometimes paired in "brain + vascular" longevity framings. Running multiple Khavinson short peptides simultaneously stacks the same single-source-evidence problem multiplicatively. Pick one per cycle, not both.
  • dylan's V4 antioxidant base (NAC, curcumin, astaxanthin, vitamin C) — likely additive if anything, no interaction concern.

Avoid stacking with

  • Other Khavinson tripeptides simultaneously (EDR/Pinealon, AED/Cerluten, Cortagen, etc.) — running multiple at once makes attribution impossible and stacks the single-source-evidence problem. Pick one per cycle.

Neutral / safe co-administration

  • Dylan's V4 base stack (citicoline, Mg L-threonate, NAC, fish oil, PS, rhodiola, theanine, B-complex)
  • Creatine, modafinil, caffeine — no interaction expected.
▸ Drug interactions deep dive
  • No documented CYP induction/inhibition. Tripeptide metabolized by peptidases, not CYP enzymes.
  • No documented interactions with Russian peptides Dylan would stack (Semax, Adamax, Cerebrolysin, Selank, Bromantane).
  • Theoretical: vasodilatory / antihypertensive additive. If KED has any real NO-axis activity, mild additive blood-pressure effect with antihypertensives is theoretically possible. Not characterized; practical impact likely minimal.
▸ Pharmacogenomics
  • None established. No published polymorphism-stratified data for Vesugen response.
  • Speculative (untested): eNOS variants, MTHFR (homocysteine handling) and ADMA-metabolism variants could in principle modulate response if the "vascular bioregulator" claim is real. None tested. Not actionable.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market Russian (oral capsule) CosmicNootropic (Vesugen® bioregulator) ~$80-100 / 60 caps High NPCRIZ-manufactured; legitimate Russian consumer product; room-temp stable. Easiest to source if you trial it; we don't recommend trialing.
Gray-market Russian (oral capsule) RUPharma (Vesugen) Comparable to CosmicNootropic High Same Russian manufacturer. Trustpilot reputation strong.
Research-chem (injectable) CosmicPeptides / Peptide Sciences / BiotechPeptides ~$60-90 / 20 mg vial Medium-High Lyophilized; cold storage and reconstitution. COA quality varies.

Cold chain

  • Oral capsule: Room temperature, <25°C, dry, dark. No special handling.
  • Injectable (lyophilized vial): Store -20°C dry, dark, before reconstitution. After reconstitution, refrigerate at 2-8°C, use within ~4 weeks.

Sourcing strategy for Dylan

Don't. No use case at his age and goals. If for some reason a vascular indication later emerges, oral capsule from CosmicNootropic / RUPharma is the lowest-friction onboarding — but the prerequisite question is "why are we running this at all?" not "where do we buy it?"

▸ Biomarkers to track (deep)

Only if running it. For Dylan's profile, the better answer is "don't run it, so no biomarker tracking needed for this compound."

If running:

  • Baseline: lipid panel, hsCRP, homocysteine, blood pressure, ADMA (if accessible). Subjective vascular VAS (cold extremities, exercise tolerance, recovery quality).
  • During use: weekly subjective VAS; no mid-cycle labs typically needed.
  • Post-cycle: repeat baseline panel 1-2 weeks post-cessation. Look for any movement in hsCRP / homocysteine / ADMA — non-movement is the expected null result.
▸ Controversies / open debates Live debate
  1. Khavinson family overall legitimacy. Same critique as pinealon's file. >300 papers across the bioregulator-peptide family over 40 years, but zero independent replication, near-total absence from ClinicalTrials.gov, methodology inconsistent with modern RCT standards, commercial conflict of interest. Honest framing: not "obvious quackery," but not "established medicine" either. Confidence appropriately discounted.
  2. Vesugen specifically is the weakest of the major Khavinson peptides. Pinealon, Epithalon, Thymalin/Thymogen all have larger internal evidence bases. Vesugen's "vascular bioregulator" claim is more monograph-driven than experiment-driven. If you're already discounting Khavinson evidence broadly, you should discount Vesugen further.
  3. No Western interest. Unlike Cerebrolysin (which has hundreds of independent papers and Western-quality RCTs in stroke) and Cortexin (which has at least some independent Russian replication outside Khavinson), Vesugen has produced essentially no signal that has prompted any Western group to follow up. That absence-of-interest is itself a weak negative signal — it's possible nobody outside the originating network found anything worth replicating.
  4. The "vascular bioregulator" tissue framing is suspect on first principles. Specific peptide → specific tissue claims (cortexin = brain, cerluten = lung, vesugen = vascular, etc.) follow a "one peptide, one organ" branding pattern that fits commercial product positioning more than mechanistic biology. Tissues are not addressed by transcription factors with that level of selectivity in the rest of biology.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW / verdict-confidence LOW. Khavinson family broad skepticism stands. Vesugen specifically has thinner internal evidence than pinealon, no compelling mechanism alignment with Dylan's profile (brain-priority, intact vasculature at 20), and zero Western replication. Sourcing is easy (RUPharma / CosmicNootropic) but the prerequisite "why" is missing. Would upgrade to OPTIONAL-ADD only if (a) independent (non-Khavinson) replication of any vascular endpoint published, (b) Dylan develops vascular pathology, or (c) bloodwork (~June 2026) flags vascular markers that no first-line option addresses better.
▸ Open questions / gaps Open
  1. Is there any independent (non-Khavinson) vascular study? Periodic re-search recommended — if a Western group publishes on KED endothelial effects, the verdict changes.
  2. What is the actual peptide content per RUPharma / CosmicNootropic capsule? Same opacity issue as pinealon. "200 mg/cap peptide complex" — actual KED content is undisclosed.
  3. Is the "vascular bioregulator" framing supported by any specific gene-target list? Pinealon has at least a published target list (CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG, GDX1). KED's target list is much sparser in available English-language literature.
  4. Does Dylan ever need this? If at 35 with elevated hsCRP / ADMA / vascular pathology, the answer might flip. At 20 with intact vasculature, the answer is no.
▸ Cross-references
  • [epithalon] — Khavinson tetrapeptide targeting telomerase / pineal melatonin axis; the strongest-evidenced compound in the Khavinson family. Vesugen rides on the family's reputation but does not contribute its own evidence base.
  • [pinealon] — sister tripeptide (EDR / Glu-Asp-Arg). Re-evaluated to WATCH-LIST after Dylan surfaced an external "Phase 3 receptor priming" claim; pinealon's mechanism story is more developed than Vesugen's. If running any Khavinson short peptide for brain-protective rationale, pinealon is the better-supported pick.
  • [cortexin] — bovine cortex peptide complex (not yet built); broader peptide hydrolysate, not a single-sequence tripeptide. Has at least some independent Russian replication. Different evidence profile from Vesugen.
  • [cerluten] — Khavinson family lung-targeted bioregulator (not yet built); shares the same single-source-evidence problem as Vesugen.
▸ Sources (full, with our context)

Primary literature

Reference / vendor / wiki

Khavinson family methodology critiques (general, also applicable to Vesugen)

Back to compact view